• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Prenetics Announces Second Quarter 2024 Financial Results

    10/7/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email

    Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024

    Enters U.S. Health Market in October with IM8, a New Health and Wellness Brand

    Re-affirms Revenue Target to Exceed US$33 million for FY 2024

    CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates.

    Second Quarter 2024 Financial Highlights

    • Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipated in the latter half of the year.
    • Gross profit from continuing operations of US$3.8 million, an increase of 23.6% as compared to the second quarter 2023.
    • Gross margin of continuing operations increased to 63.4% from 46.8% in the second quarter 2023 driven by operational efficiencies, better pricing strategies, and cost optimization measures.
    • Adjusted EBITDA1 loss from continuing operations of US$5.5 million, an improvement of 24.9% as compared to the second quarter 2023.
    • Cash and other short-term assets2 of US$78.7 million and debt-free as of June 30, 2024.
    • Insighta3, our early cancer detection joint venture with Professor Dennis Lo, had a cash balance of US$80.5 million on its balance sheet and debt-free as of June 30, 2024.

    First Half 2024 Financial Highlights

    • Revenue from continuing operations of US$12.4 million, an increase of 8.0% as compared to the first half 2023.
    • Gross profit from continuing operations of US$7.6 million, expanded by 67.6% as compared to the first half 2023.
    • Gross margin of continuing operations of 61.1%, up from 39.4% in the first half 2023.
    • Adjusted EBITDA loss from continuing operations of US$9.6 million, an improvement of 42.3% as compared to the first half 2023.

    Second Quarter 2024 and Subsequent Operational Updates

    • IM8 is fully prepared for a successful launch in October, with all marketing and operational plans in place.
    • Completed the acquisition of Europa Sports establishing IM8's diverse distribution capabilities to include a brick-and-mortar network and a 3PL logistics platform.
    • CircleDNA and ACT Genomics are on track to achieve business-unit breakeven by the second half of 2025.
    • In September, Insighta commenced a 1,500 person clinical trial for early Liver cancer detection.
    • Insighta has begun leveraging AI technologies in early cancer detection research and development efforts with considerable progress and results to be announced.

    ________________________

    1 Adjusted EBITDA is defined as loss from operations excluding (1) employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) amortization of deferred expenses, (4) acquisition and transaction-related costs, (5) strategic realignment and discontinued products impact, and (6) finance income and exchange gain or loss, net. These adjustments are made for items that may not be indicative of our business performance, including non-cash and/or non-recurring items.

    2 Represents current assets, including cash and cash equivalents totaling US$41.2 million, financial assets at fair value through profit or loss of US$10.9 million, and trade receivables of US$4.1 million, amongst other accounting line items under current assets as of June 30, 2024.

    3 As of June 30, 2024, we owned 50% shareholding in Insighta, which was accounted for under equity-accounted investee. Equity-accounted investees, totaling US$97.9 million as of June 30, 2024, were classified as non-current assets on our balance sheet.

    Management Commentary

    Danny Yeung, Chief Executive Officer and Co-Founder, remarked: "We continue to make progress in our strategic initiatives, achieving key milestones, in both our consumer and clinical health divisions. During the second quarter, we remained committed to structuring our business for operational efficiency. This can be recognized by improvements in key metrics as drivers of operating leverage, and highlighted by a 23.6% improvement in gross profit as we narrowed our adjusted EBITDA loss by 24.9% from the prior year.

    We are excited about the future as we prepare for the highly anticipated U.S. launch of IM8, our health and wellness brand. Our recent Europa acquisition provides a strong foundation and extensive global distribution network as a tailwind for IM8 to make a meaningful impact in the health and wellness market. We remain fully committed to driving growth and innovation while focusing on long-term value creation for our shareholders."

    About Prenetics

    Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our US$200 million joint venture with renowned scientist Prof. Dennis Lo, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science'. To learn more about Prenetics, please visit www.prenetics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

    Investor Relations Contact:

    [email protected]

    [email protected]

    Angela Cheung

    Investor Relations / Corporate Finance

    Prenetics Global Limited

    [email protected]

    Basis of Presentation

    Unaudited Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Non-IFRS Financial Measures".

    Unaudited Non-IFRS Financial Measures

    To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA loss from continuing operations. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

    Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) Amortization of deferred expenses, (4) Acquisition and transaction-related costs, (5) Strategic realignment and discontinued products impact, and (6) finance income and exchange gain or loss, net — items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

    In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA loss from continuing operations (Non-IFRS)" set forth at the end of this document.

    PRENETICS GLOBAL LIMITED

    Unaudited consolidated statements of financial position

    (Expressed in United States dollars unless otherwise indicated)

     June 30, March 31, December 31,
      2024  2024  2023
    Assets     
    Property, plant and equipment$4,745,228 $4,585,957 $5,777,794
    Intangible assets 12,455,997  13,169,672  13,424,648
    Goodwill 29,170,123  29,170,123  29,170,123
    Interests in equity-accounted investees 97,875,233  98,244,733  98,464,875
    Financial assets at fair value through profit or loss 9,371,064  9,371,064  9,371,064
    Deferred tax assets 27,627  27,630  27,680
    Deferred expenses —  1,483,348  3,530,756
    Other non-current assets 968,525  948,811  743,173
    Non-current assets 154,613,797  157,001,338  160,510,113
    Deferred expenses 7,710,439  8,272,025  8,312,890
    Inventories 2,878,258  2,815,607  3,126,776
    Trade receivables 4,086,030  4,106,052  4,058,007
    Deposits, prepayments and other receivables 11,797,508  5,708,610  5,284,848
    Amount due from a related company 2,561  2,556  5,123
    Amount due from an equity-accounted investee 120,966  126,177  132,114
    Financial assets at fair value through profit or loss 10,893,094  11,034,200  11,034,200
    Short-term deposits —  —  16,000,000
    Cash and cash equivalents 41,204,165  54,518,588  45,706,448
    Current assets 78,693,021  86,583,815  93,660,406
    Total assets$233,306,818 $243,585,153 $254,170,519
    Liabilities     
    Deferred tax liabilities$2,238,336 $2,327,331 $2,614,823
    Warrant liabilities 311,152  143,264  223,850
    Lease liabilities 1,181,457  669,373  867,215
    Other non-current liabilities 286,047  464,215  823,345
    Non-current liabilities 4,016,992  3,604,183  4,529,233
    Trade payables 1,693,564  1,637,568  1,671,019
    Accrued expenses and other current liabilities 6,821,131  7,100,324  8,174,815
    Contract liabilities 5,480,399  5,542,678  6,111,017
    Lease liabilities 1,183,046  1,079,449  1,502,173
    Liabilities for puttable financial instrument4 15,707,143  14,472,666  14,622,529
    Tax payable 7,402,553  7,385,897  7,402,461
    Current liabilities 38,287,836  37,218,582  39,484,014
    Total liabilities 42,304,828  40,822,765  44,013,247
    Equity     
    Share capital 19,024  18,326  18,308
    Reserves 188,225,181  199,425,243  206,339,490
    Total equity attributable to equity shareholders of the Company 188,244,205  199,443,569  206,357,798
    Non-controlling interests 2,757,785  3,318,819  3,799,474
    Total equity 191,001,990  202,762,388  210,157,272
    Total equity and liabilities$233,306,818 $243,585,153 $254,170,519



    PRENETICS GLOBAL LIMITED


    Unaudited consolidated statements of profit or loss and other comprehensive income

    (Expressed in United States dollars unless otherwise indicated)

     Six Months Ended
      June 30,   June 30, 
      2024   2023 
       (Restated)
    Continuing operations   
    Revenue$12,354,929  $11,435,274 
    Direct costs (4,804,011)  (6,930,184)
    Gross profit 7,550,918   4,505,090 
    Other income and other net gain 1,500,009   2,163,949 
    Selling and distribution expenses5 (4,314,911)  (4,672,935)
    Research and development expenses5 (5,756,508)  (5,826,315)
    Administrative and other operating expenses5 (18,747,383)  (25,911,191)
    Loss from operations (19,767,875)  (29,741,402)
    Fair value loss on financial assets at fair value through profit or loss (141,106)  (3,944,407)
    Fair value (loss)/gain on warrant liabilities (87,302)  1,752,746 
    Share of loss of equity-accounted investees (579,943)  (225,284)
    Other finance costs (43,818)  (85,243)
    Loss before taxation (20,620,044)  (32,243,590)
    Income tax credit 375,172   152,655 
    Loss from continuing operations (20,244,872)  (32,090,935)
    Discontinued operation   
    Profit/(loss) from discontinued operation, net of tax6 47,545   (1,090,255)
    Loss for the period (20,197,327)  (33,181,190)
    Other comprehensive income for the period   
    Item that may be reclassified subsequently to profit or loss:   
    Exchange difference on translation of foreign operations (770,420)  1,157,683 
    Total comprehensive income for the period$(20,967,747) $(32,023,507)
    Loss attributable to:   
    Equity shareholders of Prenetics$(19,290,049) $(32,206,003)
    Non-controlling interests (907,278)  (975,187)
     $(20,197,327) $(33,181,190)
    Total comprehensive income attributable to:   
    Equity shareholders of Prenetics$(19,926,058) $(30,533,737)
    Non-controlling interests (1,041,689)  (1,489,770)
     $(20,967,747) $(32,023,507)
    Loss per share:   
    Basic (1.58)  (3.04)
    Diluted (1.58)  (3.04)
    Loss per share - Continuing operations:   
    Basic (1.58)  (2.94)
    Diluted (1.58)  (2.94)
    Weighted average number of common shares:   
    Basic 12,219,121   10,577,069 
    Diluted 12,219,121   10,577,069 



    PRENETICS GLOBAL LIMITED


    Unaudited consolidated statements of profit or loss and other comprehensive income

    (Expressed in United States dollars unless otherwise indicated)

     Three Months Ended
     June 30,

      March 31,

      June 30,

     
      2024   2024   2023 
         (Restated)
    Continuing operations     
    Revenue$5,941,532  $6,413,397  $6,511,239 
    Direct costs (2,173,260)  (2,630,751)  (3,462,245)
    Gross profit 3,768,272   3,782,646   3,048,994 
    Other income and other net gain 752,118   747,891   1,086,858 
    Selling and distribution expenses5 (2,416,438)  (1,898,473)  (2,171,661)
    Research and development expenses5 (3,025,458)  (2,731,050)  (2,592,777)
    Administrative and other operating expenses5 (9,687,454)  (9,059,929)  (14,221,382)
    Loss from operations (10,608,960)  (9,158,915)  (14,849,968)
    Fair value loss on financial assets at fair value through profit or loss (141,106)  —   (3,944,407)
    Fair value (loss)/gain on warrant liabilities (167,888)  80,586   492,470 
    Share of loss of equity-accounted investees (363,698)  (216,245)  (112,533)
    Other finance costs (27,479)  (16,339)  (41,399)
    Loss before taxation (11,309,131)  (9,310,913)  (18,455,837)
    Income tax credit 89,234   285,938   72,000 
    Loss from continuing operations (11,219,897)  (9,024,975)  (18,383,837)
    Discontinued operation     
    Profit/(loss) from discontinued operation, net of tax6 74,160   (26,615)  (3,823,613)
    Loss for the period (11,145,737)  (9,051,590)  (22,207,450)
    Other comprehensive income for the period     
    Item that may be reclassified subsequently to profit or loss:     
    Exchange difference on translation of foreign operations (339,976)  (430,444)  1,794,185 
    Total comprehensive income for the period$(11,485,713) $(9,482,034) $(20,413,265)
    Loss attributable to:     
    Equity shareholders of Prenetics$(10,721,954) $(8,568,095) $(21,807,573)
    Non-controlling interests (423,783)  (483,495)  (399,877)
     $(11,145,737) $(9,051,590) $(22,207,450)
    Total comprehensive income attributable to:     
    Equity shareholders of Prenetics$(10,924,679) $(9,001,379) $(20,037,819)
    Non-controlling interests (561,034)  (480,655)  (375,446)
     $(11,485,713) $(9,482,034) $(20,413,265)
    Loss per share:     
    Basic$(0.88) $(0.70) $(2.06)
    Diluted (0.88)  (0.70)  (2.06)
    Loss per share - Continuing operations:     
    Basic (0.88)  (0.70)  (1.70)
    Diluted (0.88)  (0.70)  (1.70)
    Weighted average number of common shares:     
    Basic 12,222,337   12,215,904   10,597,565 
    Diluted 12,222,337   12,215,904   10,597,565 



    PRENETICS GLOBAL LIMITED


    Unaudited Non-IFRS Financial Measures

    (Expressed in United States dollars unless otherwise indicated)

    Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA loss from continuing operations (Non-IFRS)

     Six Months Ended
     June 30,

      June 30,

     
      2024   2023 
       (Restated)

     
    Loss from operations from continuing operations under IFRS$(19,767,875) $(29,741,402)
    Employee equity-settled share-based payment expenses 3,472,846   6,284,469 
    Depreciation and amortization 3,153,324   3,402,363 
    Amortization of deferred expenses 4,133,207   4,002,301 
    Acquisition and transaction-related costs 798,310   — 
    Strategic realignment and discontinued products impact 37,284   1,421,718 
    Finance income, exchange gain or loss, net (1,394,783)  (1,944,734)
    Adjusted EBITDA loss from continuing operations (Non-IFRS)$(9,567,687) $(16,575,285)



     Three Months Ended
     June 30,

      March 31,

      June 30,

     
      2024   2024   2023 
         (Restated)

     
    Loss from operations from continuing operations under IFRS$(10,608,960) $(9,158,915) $(14,849,968)
    Employee equity-settled share-based payment expenses 1,535,578   1,937,268   3,343,485 
    Depreciation and amortization 1,433,769   1,719,555   1,605,373 
    Amortization of deferred expenses 2,044,934   2,088,273   3,077,902 
    Acquisition and transaction-related costs 798,310   —   — 
    Strategic realignment and discontinued products impact 28,994   8,290   499,357 
    Finance income, exchange gain or loss, net (694,194)  (700,589)  (944,603)
    Adjusted EBITDA loss from continuing operations (Non-IFRS)$(5,461,569) $(4,106,118) $(7,268,454)

    ________________________

    4 In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the put option.

    5 Includes equity-settled share-based payment expenses from continuing operations as follows:

     Six Months Ended
     June 30, June 30,
      2024  2023
       (Restated)
    Direct costs$1,021 $—
    Selling and distribution expenses 1,463  103,868
    Research and development expenses 1,568,844  1,360,896
    Administrative and other operating expenses 1,855,743  4,778,170
    Total equity-settled share-based payment expenses$3,427,071 $6,242,934



     Three Months Ended
     June 30, March 31, June 30,
      2024  2024  2023
         (Restated)
    Direct costs$440 $581 $—
    Selling and distribution expenses 410  1,053  58,613
    Research and development expenses 810,450  758,394  874,389
    Administrative and other operating expenses 699,991  1,155,752  2,387,126
    Total equity-settled share-based payment expenses$1,511,291 $1,915,780 $3,320,128
             

    6 We ceased our COVID-19 testing business entirely in 2023 Q2, and other DNA testing operations in the EMEA regions in 2023 Q4. As a result, COVID-19 testing business and the operations in the EMEA regions are reported as a discontinued operation under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income.



    Primary Logo

    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Financials

    Live finance-specific insights

    See more
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance